

# Min Yao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016027/publications.pdf>

Version: 2024-02-01

12  
papers

227  
citations

1040056

9  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. <i>Tumor Biology</i> , 2014, 35, 9-20.	1.8	61
2	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3 $\beta$ /I $\chi$ 2-catenin axis. <i>Journal of Translational Medicine</i> , 2020, 18, 81.	4.4	33
3	Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 3829.	3.3	25
4	Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 999-1008.	1.8	17
5	Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. <i>Tumor Biology</i> , 2015, 36, 3995-4003.	1.8	16
6	Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. <i>Oncotarget</i> , 2017, 8, 52321-52332.	1.8	16
7	Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. <i>BioScience Trends</i> , 2016, 10, 337-343.	3.4	14
8	Role of secretory clusterin in hepatocarcinogenesis. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 48-48.	3.0	14
9	Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 5561-5568.	1.8	13
10	Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 453-460.	1.7	10
11	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. <i>Current Medicinal Chemistry</i> , 2020, 27, 3290-3301.	2.4	5
12	Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. <i>World Journal of Clinical Cases</i> , 2022, 10, 3321-3333.	0.8	1